Drugs organized from botulinum toxin are injected in microscopic amounts in distinct muscles that have to have treatment. The drug binds for the nerve terminals and blocks the release of acetylcholine, relaxing the targeted muscles. On August 2, 2010, the US FDA declared the acceptance of incobotulinumtoxinA (Xeomin®) to https://jetonlinepharma.us/product-category/botulinum-toxins/